Articles from Prometheus Laboratories
Prometheus Laboratories Presents Research Showing Superior Performance of MASH Precis Fibrosis Score in Identifying Treatment-Eligible Patients
Head-to-head study demonstrated better identification of treatment-eligible MASH patients while reducing uncertainty in fibrosis staging compared with ELF
By Prometheus Laboratories · Via ACCESS Newswire · November 6, 2026
Prometheus Laboratories Launches MASH Precis, a Purpose-Built Non-Invasive Test Designed to Support Evolving MASH Pathways
Blood-based test combines liver fibrosis staging and prognostic risk assessment to support patient identification, evaluation and management across MASH care pathways
By Prometheus Laboratories · Via ACCESS Newswire · October 13, 2026
Celltrion USA and Prometheus Laboratories Inc. Announce Sponsored Testing Collaboration on Anser IFX for ZYMFENTRA (infliximab-dyyb)
Celltrion Testing Access Program Expands Availability of Therapeutic Drug Monitoring to Support Patient Transition to Subcutaneous Infliximab
By Prometheus Laboratories · Via ACCESS Newswire · July 6, 2026